ERBB2 and neoplasm: Ligand-dependent and independent HER1-HER2 heterodimer levels measured by lysate and FFPE VeraTagTM assays trended with HER1 and HER2 expression levels in tumor cell lines, which was confirmed by co-immunoprecipitation.